```
=> b reg
FILE 'REGISTRY' ENTERED AT 15:42:58 ON 19 JAN 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   17 JAN 2006  HIGHEST RN 872085-61-5
DICTIONARY FILE UPDATES:  17 JAN 2006  HIGHEST RN 872085-61-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

**********************************************************************
*                                                                    *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,   *
* effective March 20, 2005.  A new display format, IDERL, is now    *
* available and contains the CA role and document type information. *
*                                                                    *
**********************************************************************

Structure search iteration limits have been increased.  See HELP SLIMITS
for details.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=> d ide can l5

L5   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2006 ACS on STN
RN   202646-79-5  REGISTRY
ED   Entered STN:  15 Mar 1998
CN   3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(2-
     thiazolylmethyl)- (9CI)  (CA INDEX NAME)
FS   3D CONCORD
MF   C21 H15 N5 O S
SR   CA
LC   STN Files:   CA, CAPLUS, TOXCENTER, USPATFULL
```




```
**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

              2 REFERENCES IN FILE CA (1907 TO DATE)
              2 REFERENCES IN FILE CAPLUS (1907 TO DATE)
```

REFERENCE 1: 134:533

REFERENCE 2: 128:154090

=> b hcap
FILE 'HCAPLUS' ENTERED AT 15:43:15 ON 19 JAN 2006

FILE COVERS 1907 - 19 Jan 2006 VOL 144 ISS 4
FILE LAST UPDATED: 18 Jan 2006 (20060118/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> d all hitstr l6 tot

L6 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2000:824128 HCAPLUS
DN 134:533
ED Entered STN: 24 Nov 2000
TI Novel use of adenosine A1A2a receptor dual antagonists
IN Matsuoka, Nobuya; Moriguchi, Akira; Tada, Miho; Mihara, Takuma
PA Fujisawa Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 61 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
IC ICM A61K-0045/00
ICS A61K-0031/4985; A61K-0031/437; A61P-0025/22; A61P-0025/24;
A61P-0025/16; C07D-0471/04; C07D-0487/04
CC 1-11 (Pharmacology)
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO2000069464	A1	20001123	2000WO-JP03015	20000511
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP---1177797	A1	20020206	2000EP-0925617	20000511
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	US2004152659	A1	20040805	2003US-0716865	20031120
PRAI	1999JP-0131108	A	19990512		
	2000WO-JP03015	W	20000511		

2001US-0926469 B1 20011108

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2000069464	ICM	A61K-0045/00
	ICS	A61K-0031/4985; A61K-0031/437; A61P-0025/22; A61P-0025/24; A61P-0025/16; C07D-0471/04; C07D-0487/04
	IPCI	A61K0045-00 [ICM,7]; A61K0031-4985 [ICS,7]; A61K0031-437 [ICS,7]; A61P0025-22 [ICS,7]; A61P0025-24 [ICS,7]; A61P0025-16 [ICS,7]; C07D0471-04 [ICS,7]; C07D0487-04 [ICS,7]
	ECLA	A61K031/00+A; A61K031/50D15; A61K031/52+A; A61K031/52+M; C07D471/04+231C+221C; A61K031/437; A61K031/4985; A61K031/50+M
EP---1177797	IPCI	A61K0045-00 [ICM,6]; A61K0031-4985 [ICS,6]; A61K0031-437 [ICS,6]; A61P0025-22 [ICS,6]; A61P0025-24 [ICS,6]; A61P0025-16 [ICS,6]; C07D0471-04 [ICS,6]; C07D0487-04 [ICS,6]
	ECLA	A61K031/00+A; A61K031/437; A61K031/4985; A61K031/50+M; A61K031/50D15; A61K031/52+A; A61K031/52+M; A61K031/522; C07D471/04+231C+221C
US2004152659	IPCI	A61K0031-7076 [ICM,7]; A61K0031-52 [ICS,7]
	NCL	514/046.000
	ECLA	A61K031/00+A; A61K031/437; A61K031/4985; A61K031/50+M; A61K031/50D15; A61K031/52+A; A61K031/52+M; A61K031/522; C07D471/04+231C+221C

OS MARPAT 134:533

GI



I



II



III

AB Preventives and/or remedies for Parkinson's disease and symptoms associating therewith such as anxiety, depression and/or memory disorder which contain as the active ingredient an adenosine A1A2a receptor dual antagonists or salts thereof. Markush's structures of pyrazolopyridine derivs. (I), pyrazolopyrazine derivs. (II), and xanthine derivs. (III) were given.

ST adenosine A receptor antagonist parkinsonism antianxiety antidepressant

IT Purinoceptor antagonists
(A1; novel use of adenosine A1A2a receptor dual antagonists in psychiatry)

IT Purinoceptor antagonists
(A2; novel use of adenosine A1A2a receptor dual antagonists in psychiatry)

IT Antidepressants
Anxiolytics
Cognition enhancers
Mental disorder
Parkinson's disease
(novel use of adenosine A1A2a receptor dual antagonists in psychiatry)
IT 69-89-6D, Xanthine, derivs. 110-86-1D, Pyridine, pyrazolo- derivs., biological studies 290-37-9D, Pyrazine, pyrazolo- derivs.
202646-79-5
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(novel use of adenosine A1A2a receptor dual antagonists in psychiatry)
RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Fujisawa Pharmaceutical Co Ltd; EP----925299 A1 HCAPLUS
(2) Fujisawa Pharmaceutical Co Ltd; WO---9803507 A1 1998 HCAPLUS
(3) Kyowa Hakko Kogyo Co Ltd; JP--06211856 A HCAPLUS
(4) Kyowa Hakko Kogyo Co Ltd; US---5484920 A HCAPLUS
(5) Kyowa Hakko Kogyo Co Ltd; US---5587378 A HCAPLUS
(6) Kyowa Hakko Kogyo Co Ltd; EP----590919 A1 1993 HCAPLUS
(7) Mally, J; Phamacol Ther 1996, V72(3), P243 HCAPLUS
(8) Mandhane, S; Eur J Pharmacol 1997, V328(2/3), P135 HCAPLUS
(9) Ohno, M; Neuroreport 1996, V7(18), P3013 HCAPLUS
(10) Suzuki, F; J Med Chem V36(17), P2508 HCAPLUS
IT **202646-79-5**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(novel use of adenosine A1A2a receptor dual antagonists in psychiatry)
RN 202646-79-5 HCAPLUS
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(2-thiazolylmethyl)- (9CI) (CA INDEX NAME)



L6 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 1998:87731 HCAPLUS
DN 128:154090
ED Entered STN: 14 Feb 1998
TI Preparation of pyrazolopyridine compounds as adenosine antagonists
IN Akahane, Atsushi; Kuroda, Satoru; Itani, Hiromichi; Shimizu, Yasuyo
PA Fujisawa Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 92 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM C07D-0471/04
ICS C07D-0453/02; A61K-0031/50; C07D-0471/04; C07D-0231/00; C07D-0221/00
CC 28-15 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO---9803507	A1	19980129	1997WO-JP02493	19970717

W: AU, CA, CN, HU, IL, JP, KR, NO, US, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

```
        RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
    CA---2260990          AA    19980129    1997CA-2260990          19970717
    AU---9734621          A1    19980210    1997AU-0034621          19970717
    AU----733034          B2    20010503
    EP----925299          A1    19990630    1997EP-0930832          19970717
    EP----925299          B1    20020925
        R: 'AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI
    CN---1230186          A     19990929    1997CN-0197819          19970717
    JP2000514821          T2    20001107    1998JP-0506791          19970717
    AT----224893          E     20021015    1997AT-0930832          19970717
    ES---2179352          T3    20030116    1997ES-0930832          19970717
    US---6124456          A     20000926    1999US-0147543          19990119
PRAI 1996AU-0001110       A     19960718
    1997WO-JP02493        W     19970717
CLASS
 PATENT NO.       CLASS  PATENT FAMILY CLASSIFICATION CODES
 --------------   -----  ----------------------------------------------
 WO 9803507       ICM    C07D-0471/04
                  ICS    C07D-0453/02; A61K-0031/50; C07D-0471/04; C07D-0231/00;
                         C07D-0221/00
                  IPCI   C07D0471-04 [ICM,6]; C07D0453-02 [ICS,6]; A61K0031-50
                         [ICS,6]; C07D0471-04 [ICS,6]; C07D0231-00 [ICS,6];
                         C07D0221-00 [ICS,6]
                  ECLA   C07D471/04+231C+221C
 CA---2260990     IPCI   C07D0471-04 [ICM,6]; C07D0519-00 [ICS,6]; A61K0031-50
                         [ICS,6]; A61K0031-505 [ICS,6]; A61K0031-535 [ICS,6];
                         A61K0031-54 [ICS,6]; A61K0031-55 [ICS,6]
 AU---9734621     IPCI   C07D0471-04 [ICM,6]; C07D0453-02 [ICS,6]; A61K0031-50
                         [ICS,6]
 EP----925299     IPCI   C07D0471-04 [ICM,6]; C07D0453-02 [ICS,6]; A61K0031-50
                         [ICS,6]; C07D0471-04 [ICI,6]; C07D0231-00 [ICI,6];
                         C07D0221-00 [ICI,6]
 CN---1230186     IPCI   C07D0471-04 [ICM,6]; C07D0453-02 [ICS,6]; A61K0031-50
                         [ICS,6]
 JP2000514821     IPCI   C07D0471-04 [ICM,7]; A61K0031-501 [ICS,7]; A61P0001-04
                         [ICS,7]; A61P0003-10 [ICS,7]; A61P0009-00 [ICS,7];
                         A61P0011-06 [ICS,7]; A61P0013-12 [ICS,7]; A61P0025-00
                         [ICS,7]; A61P0037-06 [ICS,7]; A61P0043-00 [ICS,7]
 AT----224893     IPCI   C07D0471-04 [ICM,7]; C07D0453-02 [ICS,7]; A61K0031-50
                         [ICS,7]; C07D0471-04 [ICS,7]; C07D0231-00 [ICS,7];
                         C07D0221-00 [ICS,7]
 ES---2179352     IPCI   C07D0471-04 [ICM,7]; C07D0453-02 [ICS,7]; A61K0031-50
                         [ICS,7]; C07D0471-04 [ICI,7]; C07D0231-00 [ICI,7];
                         C07D0221-00 [ICI,7]
 US---6124456     IPCI   C07D0471-04; A61K0031-497
                  NCL    514/252.040; 544/238.000
OS   MARPAT 128:154090
GI
```



I

AB The title compds. [I; R1 = aryl; R2 = lower alkyl (un)substituted with unsatd. 3 to 8-membered heteromonocyclic group, etc.] are prepared I are adenosine antagonists and are useful for the prevention and/or treatment of depression, dementia (e.g. Alzheimer's disease, cerebrovascular dementia, Parkinson's disease, etc.), anxiety, pain, cerebrovascular disease (e.g. stroke, etc.), heart failure, and the like. Thus, 3-(3-oxo-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine (preparation given) was reacted with 4-chloro-1-methyl-piperidine.HCl in the presence of NaH to give I (R1 = Ph, R2 = Me), which was tested and showed adenosine antagonistic activity.

ST pyrazolopyridine prepn adenosine antagonist; depression dementia anxiety treatment pyrazolopyridine prepn; pain cerebrovascular disease treatment pyrazolopyridine prepn; heart failure treatment pyrazolopyridine prepn

IT Adenosine receptors
RL: BPR (Biological process); BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study); PROC (Process)
(A1; preparation of pyrazolopyridine compds. as adenosine antagonists)

IT Dissociation
(Electro-mech.; preparation of pyrazolopyridine compds. as adenosine antagonists)

IT Heart, disease
(angina pectoris; preparation of pyrazolopyridine compds. as adenosine antagonists)

IT Heart, disease
(arrest; preparation of pyrazolopyridine compds. as adenosine antagonists)

IT Heart, disease
(bradyarrhythmia; preparation of pyrazolopyridine compds. as adenosine antagonists)

IT Brain, disease
(cerebrovascular; preparation of pyrazolopyridine compds. as adenosine antagonists)

IT Intestine, disease
(constipation; preparation of pyrazolopyridine compds. as adenosine antagonists)

IT Mental disorder
(dementia; preparation of pyrazolopyridine compds. as adenosine antagonists)

IT Mental disorder
(depression; preparation of pyrazolopyridine compds. as adenosine antagonists)

IT Heart, disease
Kidney, disease
(failure; preparation of pyrazolopyridine compds. as adenosine antagonists)

IT Intestine, disease
(ileus; preparation of pyrazolopyridine compds. as adenosine antagonists)

IT Heart, disease
(infarction, myocardial; preparation of pyrazolopyridine compds. as adenosine antagonists)

IT Brain, disease
(infarction; preparation of pyrazolopyridine compds. as adenosine antagonists)

IT Brain, disease
(ischemia, transient; preparation of pyrazolopyridine compds. as adenosine antagonists)

IT Intestine, disease
(ischemia; preparation of pyrazolopyridine compds. as adenosine antagonists)

IT Kidney, disease
(nephritis; preparation of pyrazolopyridine compds. as adenosine antagonists)

IT Arteriosclerosis
(obliterans; preparation of pyrazolopyridine compds. as adenosine antagonists)

IT Pancreas, disease
(pancreatitis; preparation of pyrazolopyridine compds. as adenosine antagonists)

IT Alzheimer's disease
Anemia (disease)

Anxiety
Asthma
Diabetes mellitus
Edema
Gout
Hypertension
Immunosuppression
Kidney, disease
Multiple organ failure
Multiple organ failure
Obesity
Pain
Parkinson's disease
Shock (circulatory collapse)
Thrombosis
Ulcer
(preparation of pyrazolopyridine compds. as adenosine antagonists)

IT Toxicity
(renal; preparation of pyrazolopyridine compds. as adenosine antagonists)

IT Respiration, animal
Respiration, animal
Therapy
Therapy
(resuscitation, post; preparation of pyrazolopyridine compds. as adenosine antagonists)

IT Brain, disease
(stroke; preparation of pyrazolopyridine compds. as adenosine antagonists)

IT Death
(sudden infant death syndrome; preparation of pyrazolopyridine compds. as adenosine antagonists)

IT Inflammation
(systemic inflammatory response syndrome; preparation of pyrazolopyridine compds. as adenosine antagonists)

IT Vein
(thrombophlebitis; preparation of pyrazolopyridine compds. as adenosine antagonists)

IT 69-93-2, biological studies
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(hyperuricemia; preparation of pyrazolopyridine compds. as adenosine antagonists)

IT **202646-79-5P** 202646-80-8P 202646-82-0P 202646-84-2P
202646-85-3P 202646-87-5P 202646-89-7P 202646-90-0P 202646-91-1P
202646-92-2P 202646-93-3P 202646-94-4P 202646-95-5P 202646-96-6P
202646-97-7P 202646-98-8P 202646-99-9P 202647-00-5P 202647-01-6P
202647-02-7P 202647-03-8P 202647-04-9P 202647-05-0P 202647-06-1P
202647-07-2P 202647-08-3P 202647-09-4P 202647-10-7P 202647-11-8P
202647-12-9P 202647-13-0P 202647-14-1P 202647-15-2P 202647-23-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrazolopyridine compds. as adenosine antagonists)

IT 106-52-5, 1-Methyl-4-hydroxypiperidine 498-94-2, Isonipecotic acid
501-53-1, Benzyl chloroformate 867-13-0, Triethylphosphonoacetate
2032-35-1, Bromoacetaldehyde diethyl acetal 5382-16-1,
4-Hydroxypiperidine 5382-23-0, 4-Chloro-1-methylpiperidine hydrochloride
24424-99-5, Di-tert-butyl dicarbonate 41979-39-9, 4-Piperidone
hydrochloride 50893-53-3, 1-Chloroethyl chloroformate 79099-07-3,
1-tert-Butoxycarbonyl-4-piperidone 104706-47-0 141060-69-7
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of pyrazolopyridine compds. as adenosine antagonists)

IT 533-15-3P 3518-83-0P 4045-22-1P 19099-93-5P 20691-89-8P
21156-84-3P 77211-75-7P 84358-13-4P 86518-68-5P 105409-83-4P
109384-19-2P 109431-87-0P 118811-03-3P 135716-08-4P 135716-09-5P
141430-49-1P 202647-16-3P 202647-17-4P 202647-18-5P 202647-19-6P
202647-20-9P 202647-21-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT

(Reactant or reagent)
(preparation of pyrazolopyridine compds. as adenosine antagonists)
RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Fujisawa Pharmaceutical Co Ltd; EP---0379979 A 1990 HCAPLUS
(2) Fujisawa Pharmaceutical Co Ltd; EP---0467248 A 1992 HCAPLUS
(3) Fujisawa Pharmaceutical Co Ltd; WO---9325205 A 1993 HCAPLUS
(4) Fujisawa Pharmaceutical Co Ltd; WO---9518128 A 1995 HCAPLUS
(5) Uehara, Y; AM J HYPERTENS 1995, V8(12, PT 1), P1189
IT **202646-79-5P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrazolopyridine compds. as adenosine antagonists)
RN 202646-79-5 HCAPLUS
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(2-thiazolylmethyl)- (9CI) (CA INDEX NAME)



=> => b uspatall
FILE 'USPATFULL' ENTERED AT 15:48:49 ON 19 JAN 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 15:48:49 ON 19 JAN 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

=> d bib abs hitstr l8 tot

L8 ANSWER 1 OF 2 USPATFULL on STN
AN 2004:197353 USPATFULL
TI Method for the treatment of parkinson's disease comprising administering an A1A2a receptor dual antagonist
IN Matsuoka, Nobuya, Souraku-gun, JAPAN
Moriguchi, Akira, Ibaraki-shi, JAPAN
Tada, Miho, Amagasaki-shi, JAPAN
Mihara, Takuma, Ikoma-gun, JAPAN
PA Fujisawa Pharmaceutical Co. Ltd., Osaka-shi, JAPAN (non-U.S. corporation)
PI US2004152659 A1 20040805
AI 2003US-0716865 A1 20031120 (10)
RLI Continuation of Ser. No. 2001US-0926469, filed on 8 Nov 2001, ABANDONED A 371 of International Ser. No. 2000WO-JP03015, filed on 11 May 2000, UNKNOWN
PRAI 1999JP-0131108 19990512
DT Utility
FS APPLICATION
LREP OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT, P.C., 1940 DUKE STREET, ALEXANDRIA, VA, 22314
CLMN Number of Claims: 18
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1534
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Preventives and/or remedies for Parkinson's disease and symptoms associating therewith such as anxiety, depression and/or memory disorder

which contain as the active ingredient an adenosine A.sub.1A.sub.2a receptor dual antagonist or salts thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **202646-79-5**
(novel use of adenosine A1A2a receptor dual antagonists in psychiatry)
RN 202646-79-5 USPATFULL
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(2-thiazolylmethyl)- (9CI) (CA INDEX NAME)



L8 ANSWER 2 OF 2 USPATFULL on STN
AN 2000:128488 USPATFULL
TI Pyrazolopyridine compound and pharmaceutical use thereof
IN Akahane, Atsushi, Hyogo, Japan
Kuroda, Satoru, Takatsuki, Japan
Itani, Hiromichi, Hyogo, Japan
Shimizu, Yasuyo, Osaka, Japan
PA Fujisawa Pharmaceutical Co., Ltd., Osaka, Japan (non-U.S. corporation)
PI US---6124456 20000926
WO---9803507 19980129
AI 1999US-0147543 19990119 (9)
1997WO-JP02493 19970717
19990119 PCT 371 date
19990119 PCT 102(e) date
PRAI 1996AU-0001110 19960718
DT Utility
FS Granted
EXNAM Primary Examiner: Gerstl, Robert
LREP Oblon, Spivak, McClelland, Maier & Neustadt, P.C.
CLMN Number of Claims: 14
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1690
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A pyrazolopyridine compound of formula (I) wherein R.sup.1 is aryl, and R.sup.2 is lower alkyl substituted with unsaturated 3 to 8-membered heteromonocyclic group containing 1 or 2 sulfur atom(s) and 1 to 3 nitrogen atom(s) which may have one or more substituent(s); a group of formula (1) wherein R.sup.3 is hydrogen, lower alkyl, ar(lower)alkyl or acyl, R.sup.4 is hydrogen or hydroxy, A is lower alkylene, m is an integer of 0 or 1, and n is an integer of 1 or 2; a group of formula (2) wherein R.sup.5 and R.sup.6 are each lower alkyl; or quinuclidinyl, or a salt the The pyrazolopyridine compound (I) and a salt thereof of the present invention are adenosine antagonists and are useful for the prevention and/or treatment of depression, dementia (e.g. Alzheimer's disease, cerebrovascular dementia, Parkinson's disease, etc.), anxiety, pain, cerebrovascular disease (e.g. stroke, etc.), heart failure, and the like.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **202646-79-5P**
(preparation of pyrazolopyridine compds. as adenosine antagonists)
RN 202646-79-5 USPATFULL
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(2-thiazolylmethyl)- (9CI) (CA INDEX NAME)



```
=> d his

     (FILE 'HOME' ENTERED AT 14:56:13 ON 19 JAN 2006)

     FILE 'HCAPLUS' ENTERED AT 14:58:04 ON 19 JAN 2006
L1             2 US2004152659/PN OR (US2003-716865# OR JP2000-3015# OR US2001-92
                 SEL AN 1
L2             1 E1-2 AND L1

     FILE 'REGISTRY' ENTERED AT 14:58:40 ON 19 JAN 2006

     FILE 'HCAPLUS' ENTERED AT 14:58:40 ON 19 JAN 2006
L3               TRA L2 1- RN :         4 TERMS

     FILE 'REGISTRY' ENTERED AT 14:58:40 ON 19 JAN 2006
L4             4 SEA L3

     FILE 'HCAPLUS' ENTERED AT 14:58:51 ON 19 JAN 2006

     FILE 'REGISTRY' ENTERED AT 14:59:18 ON 19 JAN 2006
                 SEL RN 1
L5             1 E3 AND L4

     FILE 'HCAPLUS' ENTERED AT 15:39:35 ON 19 JAN 2006
L6             2 L5

     FILE 'HCAOLD' ENTERED AT 15:41:11 ON 19 JAN 2006
L7             0 L6

     FILE 'USPATFULL, USPAT2' ENTERED AT 15:41:48 ON 19 JAN 2006
L8             2 L5

=>
```